Stallergenes Group, a global healthcare group specializing in the diagnosis and treatment of respiratory allergies, has successfully raised a revolving credit facility amounting to EUR 50 million. The facility takes the form of a revolving credit line composed of one single tranche and is provided by UBS Switzerland AG. The new revolving credit facility, which is subject to customary closing conditions, is for general corporate and working capital purposes and the refinancing of an existing facility of Stallergenes Group.
Baker McKenzie advised UBS Switzerland AG in connection with the structuring and documentation of the EUR 50 million Swiss law governed revolving credit facility and the related security documentation. The Baker & McKenzie team was led by Lukas Glanzmann (Partner) and Philip Spoerlé (Associate) who were supported by teams in London, Paris, Chicago and Houston.